Aris Global plans 50 hires for pharma software outpost in Ireland

Pharma software provider Aris Global aims to hire 50 workers for a planned office in Dublin with support from the Irish government. Officials in Ireland have welcomed the arrival of the U.S. software company as the government hustles to attract foreign investment to revive the country's wounded economy. 

Stamford, CT-based Aris--which provides software for monitoring drug safety, research and development and medical information--aims to open shop in Dublin and boost its European presence as part of a global expansion. The company already employs about 700 workers in the U.S., U.K., India, Europe and Japan. IDA Ireland, which works on attracting foreign investment to Ireland, worked on bringing Aris to Dublin, according to a press release.

Ireland has targeted foreign investment from tech and life sciences companies, and the high-paying jobs that come with those investments, as part of the government's efforts to promote economic growth. According to BusinessWeek, Ireland's housing market crisis in 2008 injured the economy and foreign investment is expected to be key to its economic recovery.

Ireland has attracted other life sciences companies from the U.S. such as Alkermes ($ALKS), which established its corporate headquarters in the country with the drugmaker's purchase of Elan Drug Technologies last year. Ireland has lured outside investment with the help of its low corporate taxes, government incentives, trained work force, and access to the European market.

Deepak Abbhi, president and CEO of Aris, said in a statement: "The expansion of the European operations of Aris Global in Ireland will enable us to take the lead in providing cloud-based solutions for pharmaceutical research and development. In addition, this expansion will strengthen sales and marketing and services delivery for the company's European market as part of our global expansion."

- here's the release
- see The Irish Times article

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

The $58 million financing round represents biopharma industry's growing interest in genomics data.

Clinerion inks a new deal that adds 60 million U.S. patients to its clinical trial patient recruitment system.